Last mentioned: Mar 23, 2026
JPM Q1 Earnings Report
JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
JPM Earnings
JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
FDA Orforglipron Decision
Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
FDA Decision Date
Expected regulatory ruling on orforglipron oral weight loss drug.
Earnings Release
Both companies report Q4 and FY 2025 financial results and business highlights.
FDA Partial Hold
FDA notifies PepGen of partial clinical hold on Freedom2 trial.
Fiscal Year End
OmniAb and PepGen conclude their 2025 fiscal years.
Zepbound Approval
FDA expands tirzepatide approval to include chronic weight management.
Mounjaro Launch
Tirzepatide enters the market for Type 2 Diabetes treatment.
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.
The U.S. Food and Drug Administration is introducing a landmark performance-based bonus system for staff members who complete drug application reviews ahead of schedule. This shift toward private-sector incentive models aims to clear regulatory backlogs and accelerate patient access to new therapies.
The U.S. Food and Drug Administration is moving to eliminate the long-standing requirement for two pivotal clinical trials for new drug approvals. This regulatory shift aims to significantly reduce the time and cost of drug development, prioritizing faster patient access to innovative therapies.